Previous Page Next Page


Repotrectinib (repotrectinib, TPX-0005) is an orally-available multi-kinase inhibitor designed to overcome resistance due to solvent-front substitutions involving TRKA, TRKB, and TRKC proteins as well as those involving ROS1, and ALK [1, 2]. Repotrectinib is smaller than most other TRK/ROS/ALK protein inhibitors and can cross the blood–brain barrier, thereby suggesting potential CNS activity.


  1. Drilon A, Ou SI, Cho BC et al. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov 2018; 8: 1227-1236.
  2. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings